“Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy”, Clinics, vol. 76, p. e3146, Oct. 2021, doi: 10.6061/clinics/2021/e3146.